Clinical trials: Incretins
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
GLP-1, Obesity &Amp; Overweight
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are…
- Conditions
- GLP-1, Obesity &Amp; Overweight, Dietary Supplement
- Trial name
- NCT07240246
- Testing
- Intervention: Dietary Supplement with Plant Extracts
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
Gastroparesis, Diabetes Mellitus
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy…
- Trial name
- NCT00501657
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Royal Adelaide Hospital
Obesity (BMI>30)
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is…
- Trial name
- RESIST (NCT07777575)
- Testing
- Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Technical University of Munich
Obesity
Comparison of Body Composition Changes With Weight Loss Interventions
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time.
- Trial name
- REFORM (NCT07115069)
- Testing
- GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Hyperlipidemias, Nutritional and Metabolic Diseases
Lean Seafood Intake and Postprandial Metabolism
Despite numerous studies of meal components in humans, little is still known about how different meals influence on metabolism. The purpose of this study is to a gain knowledge of how a balanced test meal with either lean seafood…
- Conditions
- Hyperlipidemias, Nutritional and Metabolic Diseases, Nutrition Disorders, Metabolic Diseases
- Trial name
- LeSIP (NCT01708681)
- Testing
- Lean seafood, Meat, egg, milk
- Where
- Norway
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Nutrition and Seafood Research, Norway
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich
Insulin Secretion
Regulation of Insulin Secretion by the GLP-1 Receptor
AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance.
- Trial name
- NCT02844907
- Testing
- Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Obesity & Overweight
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
This is a single-center, randomized, participant-blinded, sham-controlled trial designed to evaluate the adjunctive effect of transcutaneous auricular vagus nerve stimulation (taVNS) in overweight or obese patients who show a…
- Trial name
- NCT07619989
- Testing
- transcutaneous auricular vagus nerve stimulation
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Type 2 Diabetes
A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)
This study will determine the effect of concomitant administration of sitagliptin and metformin on post-meal incretin hormone concentrations in healthy adults.
- Trial name
- NCT00975052
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: sitagliptin and metformin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Incretin Therapy and Exercise in Type 2 Diabetes
This study will examine changes in brain and physical health in adults with type 2 diabetes who are initiating incretin-mimetic therapy (e.g., Ozempic, Mounjaro), and determine whether adding structured exercise provides…
- Trial name
- BIOM (NCT07833813)
- Testing
- Structured Exercise Program
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- University of Regina
Diabetes, Diabetes Mellitus, Type 1
Liraglutide as add-on to Insulin in Type 1 Diabetes
The purpose of this study is to: Part 1: To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.
- Trial name
- T1DMLIRA (NCT02092896)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00698932
- Testing
- Saxagliptin
- Where
- 30 sites in China, India and 2 more
- Volunteers
- 568 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes…
- Trial name
- DM200-101 (NCT00638716)
- Testing
- CJC-1134-PC
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- ConjuChem
Type 2 Diabetes Mellitus
Incretin-based Drugs and the Risk of Heart Failure
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure…
- Trial name
- NCT02456428
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,499,650 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type 1 Diabetes
Incretin Effect on the Immunological Phenotype
Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes
- Trial name
- NCT01782261
- Testing
- Liraglutide, Saxagliptin
- Where
- Austria
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Obesity
Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients
The aim of our study is to investigate the effects of high-protein diet on satiety and incretin hormones in patients with diabetes.
- Trial name
- NCT01678742
- Testing
- High-protein diet, Standard diet
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Jeju National University Hospital
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Type 2 Diabetes, NAFLD
Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients
Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and…
- Trial name
- NIMROD (NCT05654805)
- Testing
- Drinking powder supplement
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- Charite University, Berlin, Germany